Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above Two Hundred Day Moving Average - Here's Why

Key Points

• Cumberland Pharmaceuticals shares broke above their 200-day moving average, reaching $7.87 before trading at $7.65, compared with a 200-day average of $5.04.
• Analyst sentiment remains negative: Weiss Ratings maintained a “sell” rating, Wall Street Zen downgraded the stock to “hold,” and MarketBeat reports an average rating of “Sell.”
• The company reported disappointing quarterly results, with an adjusted loss of $0.20 per share versus the $0.13 expected and revenue of $0.17 million against an $8.50 million consensus estimate.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.04 and traded as high as $7.87. Cumberland Pharmaceuticals shares last traded at $7.65, with a volume of 69,395 shares.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CPIX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen downgraded Cumberland Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cumberland Pharmaceuticals has an average rating of "Sell".

Cumberland Pharmaceuticals Trading Up 0.3%

The stock's 50-day moving average is $6.79 and its 200-day moving average is $5.04. The firm has a market capitalization of $114.60 million, a price-to-earnings ratio of -10.77 and a beta of 0.08.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative return on equity of 28.81% and a negative net margin of 34.40%.The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $8.50 million.

Cumberland Pharmaceuticals Announces Dividend

The business also recently declared a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 23rd were given a $1.50 dividend.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in CPIX. XTX Topco Ltd bought a new stake in Cumberland Pharmaceuticals in the second quarter valued at approximately $34,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Cumberland Pharmaceuticals in the 1st quarter worth approximately $66,000. Two Sigma Investments LP boosted its stake in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company's stock valued at $117,000 after purchasing an additional 5,326 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Cumberland Pharmaceuticals during the fourth quarter worth $192,000. Finally, Bank of New York Mellon Corp bought a new position in Cumberland Pharmaceuticals during the second quarter worth $379,000. 15.51% of the stock is owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source